ASX ANNOUNCEMENT

Lumos to Present at 20th Bioshares Biotech Summit

MELBOURNE, Australia (7 August 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, "Lumos" or the "Company") a leader in rapid, point-of-care diagnostic technologies, is pleased to provide a copy of the presentation to be delivered today at the 20th Bioshares Biotech Summit in Queenstown, New Zealand.

Session details

Presenter: CEO and Managing Director, Doug Ward

Date: Friday, 7 August 2026

Time: 3:05pm

Session: Session 7: Fighting Infections

The presentation is appended with this announcement, and a full copy of the conference program is available via this link: www.bioshares.com.au.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598

Lumos Diagnostics Holdings Limited

Bioshares Presentation - Fighting Infection

7 August 2026

lumosdiagnostics.com

Disclaimer and Important Information

This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Non-IFRS financial measures

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, at the point-of-care.

Improving the practice of medicine.

Company Snapshot

ASX: LDX · CAPITAL STRUCTURE AS AT 30 JULY 2026 · 24-MONTH SHARE PRICE AND EXECUTION MILESTONES

ISSUED CAPITAL	
Shares on issue	**944.4m**
Options — investors	**86.8m**
Options & rights — employees	**82.0m**

MARKET CAPITALISATION (AUD)	
Share price[1]	**A$0.11**
Market value	**A$103.9m**
Cash[2]	**A$22.0m**
Enterprise value	**A$81.9m**

SUBSTANTIAL SHAREHOLDERS	
Tenmile Ventures	**19.8%**
Ryder Capital	**14.4%**

1 **Dec 24** CPT PLA code secured

2 **Apr 25** Two MAC coverage decisions

3 **Jul 25** PHASE exclusive US distribution

4 **Oct 25** WellStreet "FebriDx-first" protocol

5 **Mar 26** 510(k) with CLIA waiver + A$20m capital raise

6 **Jul 26** 170+ sites live across 24 states

A$81.9m
Enterprise value

US$317m
Minimum contracted value under the PHASE Scientific US distribution agreement

Board and management Sam Lanyon Non-Executive Chairman · Doug Ward CEO & Managing Director · Bronwyn Le Grice, Lawrence Mehren and Catherine Robson Non-Executive Directors · Barrie Lambert Chief Financial Officer

[1] Share price as at 30 July 2026. [2] Cash as at 30 June 2026, based on a USD FX conversion rate of 0.70. PHASE Scientific minimum contracted value as previously announced. Share price chart: ASX daily closing prices to 4 August 2026.

FY26 highlights

YEAR ENDED 30 JUNE 2026 · CLEARED, COVERED, CONTRACTED

US$13.2m
FULL YEAR REVENUE

60%
FEBRIDX PRODUCT GROSS MARGIN

US$15.4m
CASH AT 30 JUNE 2026

WELL CAPITALISED
Funding the US commercial rollout

A UNIQUE IVD
Bacterial or non-bacterial after ten minutes, from a fingerstick blood sample

DE-RISKED PATHWAY
FDA-cleared, CLIA-waived and reimbursed at US$41.38

MARKET >US$1.0BN
300,000 US sites and 80 million acute respiratory infection visits a year

US$317m
Minimum contracted value under the PHASE Scientific agreement

A$81.9m
Enterprise value at 30 July 2026

FY26 is the twelve months ended 30 June 2026. Revenue and cash stated in USD; cash of US$15.4m equates to A$22.0m at an FX conversion rate of 0.70. Reimbursement: CPT PLA code 0442U, US$41.38 per test. Gross margin shown is FebriDx product gross margin. Addressable site and visit volumes: Company market analysis. Minimum contracted value and enterprise value as previously reported.

FebriDx® - Reducing Antibiotic Overprescription

Novel proprietary point-of-care test for distinguishing between bacterial versus non-bacterial symptoms

The Problem

High Patient Volume and Diagnostic Uncertainty Drive Unnecessary Antibiotic Use

- Difficulty differentiating **bacterial** infections from **non-bacterial** etiology due to overlapping clinical symptoms
- **High volume** of Acute Respiratory Infection (ARI) patients **daily**
- **Time** to assess each patient is short
- Limitations in **rapid tests** to diagnose acute respiratory infections
- Patient **expectations** to receive an antibiotic vs. avoiding intervention

Our Solution: FebriDx®
Point-of-care test to guide antibiotic treatment decisions

LUMOS DIAGNOSTICS

FebriDx® can rapidly identify patients who have a microbial infection[1] and, if positive, determine if that infection is caused by a viral or bacterial pathogen after 10 minutes

What is FebriDx®?

FebriDx® test procedure and interpretation of results



Patient can be treated with antibiotics

Viral infection – antibiotics will not work
Patient needs to be managed differently

What has it achieved?[2]

10min
to deliver a result leaves patients with actionable plan of trust

>99%
accuracy for ruling out bacterial infection

>90%
accuracy in differentiating viral vs. bacterial infection

Source: (1) Microbial infection is the invasion of infectious agents into the organism, their multiplication and the reaction of host tissue against these agents. Infectious agents include bacteria, virus, parasite and fungi. (2) Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting, Nathan I. Shapiro,MD, MPH, JAMA Network, 18 October 2022.

A Workflow Solution, not just a diagnostic

EMBEDDED AT TRIAGE · EVERY ELIGIBLE PATIENT · RECURRING REVENUE



01	Embedded in protocol — ordered for every eligible patient
02	Seamless integration into the existing triage workflow
03	Recurring revenue and margin across the care continuum
04	Better clinical decisions and better care for respiratory patients

THE PROOF POINT

"FebriDx-first" protocol

WellStreet made FebriDx the default order at triage for every eligible patient.

165
URGENT CARE SITES

>1.2m
RESPIRATORY VISITS A YEAR

Revenue scales with patient visit volume

WellStreet Urgent Care site count and annual acute respiratory visit volume as publicly reported by WellStreet.

From Regulatory Validation to Revenue Scale-Up

COMMERCIAL PROOF NOW MATTERS MORE THAN REGULATORY MILESTONES

01 VALIDATION → **02 COMMERCIAL ADOPTION** → **03 SCALED UTILISATION** → **04 REVENUE SCALE-UP**

WE ARE HERE

COMPLETE

- FDA 510(k) with CLIA waiver granted
- 100% Medicare MAC recognition
- Dedicated PLA code 0442U

UNDERWAY

- US$5.0m Phase pre-payment
- 170+ live sites across 24 states
  - Two Top 100 urgent care accounts
- 350 sites in active evaluation
  - Three Top 100 urgent care accounts

NEXT

- “FebriDx-first” protocol at triage
- Drive utilization rate within top 100 urgent care groups
- Tests per site per month compounding

OUTCOME

- US$317m minimum contract converts based on MOQs
- Carlsbad capacity ready for 26/27 flu season
- Path to self-funded growth

Execution risk has shifted from regulatory approval to rollout velocity and revenue conversion

CLIA Waiver Label expands TAM to > US$1.0 Billion

Two key US market opportunities for testing are in urgent care and primary care sites, these have formed our target sites as we commercialise FebriDx®

US market opportunities in acute respiratory infection testing[1]



2026 US market data demonstrates the opportunity

270k
CLIA Waived Locations

14k[2]
Urgent Care Locations

160k[3]
Primary Care Locations

174k
potential US urgent care and primary care sites

~68 million
ARI visits to US urgent care and primary care sites

Source: (1) Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid Services, March 2024 (CMS CLIA Data base). (2) Precision Business Insights, US Acute Respiratory Infections, 2024.(2) The Journal of Urgent Care Medicine, https://www.jucm.com/2024-urgent-cares-top-100-by-number-of-locations/. (3) CMS CLIA Database, March 2024 (Division of Clinical Laboratory Improvement and Quality, Centers for Medicare & Medicaid Services); U.S. urgent-care industry data; Precision Business Insights, 'US Acute Respiratory Infections', 2024. Estimated primary care site count (~160k) is a Lumos internal estimate derived from these data.

US $317M minimum PHASE Scientific US distribution agreement

One of the largest point of care diagnostic deals for an ASX listed diagnostics company

Summary of anticipated payments

Milestones	Payment timing	With CLIA waiver (US$m)
Exclusivity fee	Received (on-signing)	$1.0
Pre-paid purchase order	Received (on-signing)	$1.0
Pre-paid purchase order	Received (on CLIA waiver application submission)	$1.5
Prep-paid purchase commitment	Received (on grant of CLIA waiver)	$5.0
Aggregated minimum order quantities (yrs 2-6)	On delivery of product	$308.5
	Total	**$317.0**

Summary of key terms

- Six-year term, with option to extend
- Exclusive rights to distribute and commercialise FebriDx® under the Lumos brand in the US
- Lumos retains all IP rights, manufacturing, quality control and product compliance
- Minimal contract value of US$317m – based on CLIA waiver grant and all MOQ's are achieved
- Regular business reviews to assess performance

Margin at Every Step of the Channel

SELF-SUSTAINING ECONOMICS AT THE PUBLISHED MEDICARE RATE

FebriDx® is reimbursed at US$41.38 per test — enough to support a healthy margin for Lumos, its distribution partners and the treating physician. No participant in the chain depends on a price concession.

01 LUMOS	02 PHASE SCIENTIFIC	03 SUB-DISTRIBUTORS	04 PHYSICIAN
60%+	**30%+**	**20%-30%**	**$41.38**
Product gross margin	**Distributor margin**	**Channel margin**	**Reimbursed per test (US$)**
Manufacture, IP and quality control retained in-house at Carlsbad, CA	Exclusive U.S. distributor with a dedicated field sales force	Regional reach into Tier 1 and Tier 2 urgent care networks	Acquisition cost leaves a positive margin on every test billed

Every participant is profitable at the published reimbursement rate — the channel scales without margin subsidy

Product gross margin as previously disclosed by the Company. Partner and channel margins are indicative ranges and vary with volume, mix and contract terms. Reimbursement: PLA 0442U, CMS clinical laboratory fee schedule (US$41.38 per test).

Partner Ecosystem Accelerates Adoption

LUMOS OWNS THE PRODUCT · SPECIALIST PARTNERS SUPPORT THE U.S. COMMERCIAL ENGINE

LUMOS DIAGNOSTICS

PRODUCT OWNER & MANUFACTURER · FEBRIDX COMMERCIAL LEADER

PHASE SCIENTIFIC

EXCLUSIVE U.S. DISTRIBUTOR

Management of sub distributors
Tier 1 & 2 urgent care reach
with dedicated sales force

6-year agreement

acuityMD

CLAIMS DATA INTELLIGENCE

Targets highest-value accounts
by volume and payer mix

Pipeline targeting

PROspectus

REIMBURSEMENT SUPPORT

Site onboarding, billing setup
and claims tracking

Revenue enablement

cglife

MARKETING PARTNER

PR, brand and omnichannel
demand generation

Brand & PR

FebriDx® — Three pillars of commercial adoption

ALL THREE PILLARS VALIDATED · COMMERCIAL READINESS CONFIRMED

01 CLINICAL BENEFIT

99%

NPV to rule out bacterial ARI

Only POC test separating bacterial from viral at triage

~40% of ARI antibiotics are unnecessary

✓ VALIDATED

02 ECONOMIC BENEFIT

$41.38

per test — PLA 0442U, CMS 2025

100% Medicare MAC recognition, all U.S. regions

Private payor coverage expanding

✓ VALIDATED

03 OPERATIONAL EFFICIENCY

10 min

to result · ~1 min hands-on

Instrument-free, CLIA-waived — no capital equipment

Runs alongside COVID/Flu combo tests

✓ VALIDATED

Lumos and PHASE Launch Focus – Top 100 urgent care groups

Top 100 operators control 40% of urgent care sites



Source: Journal of Urgent Care Medicine, 1 April 2025

The Playbook that scales point-of-care diagnostics

FOUR PILLARS OF SCALED ADOPTION · WHERE LUMOS STANDS · PROVEN IN THE WELLSTREET URGENT CARE NETWORK

PILLAR	WHAT BEST-IN-CLASS LOOKS LIKE	WHERE LUMOS STANDS
01 **Protocol-led rollout**	Test embedded as the default clinical protocol; pilots expand network-wide	✓ "FebriDx-first" protocol live at WellStreet — a replicable model
02 **Reimbursement clarity**	Clear billing pathways, high consistency across payors, low denial rates	✓ Medicare established at US$41.38 with 100% MAC recognition
03 **Capital-light distribution**	Leverage existing networks rather than building fixed-cost sales infrastructure	✓ PHASE agreement delivers scaled US reach without a large Lumos field sales force
04 **Real-world evidence**	Evidence at scale supports guidelines, payor expansion and differentiation	✓ 170+ live sites and 350 in evaluation generate a compounding dataset



PROVEN IN NETWORK

WellStreet Urgent Care

Georgia · Michigan · Ohio · South Carolina

The "FebriDx-first" protocol is live across this network

165
URGENT CARE SITES

>1.2m
RESPIRATORY VISITS A YEAR

WellStreet Urgent Care site count, footprint and annual visit volumes as publicly reported by WellStreet. Reimbursement: CPT PLA code 0442U, CMS clinical laboratory fee schedule, US$41.38 per test.

Strong Commercial Traction in under 4 months

350 SITES IN EVALUATION · 170+ SITES LIVE ACROSS 24 STATES

PIPELINE FUNNEL



01 IN EVALUATION

Clinical & economic validation underway

350	1.4m-1.9m	3 Top 30
Sites in active evaluation	Estimated ARI visits per annum	Urgent Care Groups engaged, incl. Top 10, Top 25 and Top 30

Pipeline spans the largest U.S. urgent care networks

02 LIVE & SCALING

Network rollout in market

170+	24	680k-935k	>90%
Live sites	States covered	Estimated ARI visits per annum	Payment coverage at US$41.38 / test

Includes two Top 100 urgent care accounts — all achieved in under four months

FebriDx is manufactured in Carlsbad, California

VERTICALLY INTEGRATED MANUFACTURING · ISO 13485 CERTIFIED · NEW FACILITY OPENS THIS YEAR

NEW LUMOS FACILITY · CARLSBAD, CALIFORNIA

FebriDx is not outsourced. Every test is made by Lumos in Carlsbad.

60%
PRODUCT GROSS MARGIN at launch

10m
TESTS A YEAR ONCE NEW FACILITY VALIDATED

ISO 13485
CERTIFIED FACILITY

01 Control of cost and quality

In-house production protects margin and supply for a US-reimbursed product

02 New facility opens by year end

Once validated it lifts capacity to up to 10 million tests a year

03 Ahead of demand, not behind it

The current site already covers more than two years of forecast volume

US-based manufacturing keeps margin, quality and supply under Lumos control

New Lumos facility in Carlsbad, California, scheduled to open by end CY2026; stated annual capacity subject to completion of validation. Margin and capacity as previously reported.

Thank You

Lumos Diagnostics Holdings Limited | ASX: LDX

ir@lumosdiagnostics.com · lumosdiagnostics.com

This presentation contains forward-looking statements. Past performance is not necessarily indicative of future results.